Tevogen Begin Period Cash Flow from 2010 to 2025

TVGN Stock   1.20  0.03  2.56%   
Tevogen Bio Begin Period Cash Flow yearly trend continues to be very stable with very little volatility. Begin Period Cash Flow is likely to grow to about 175.1 K this year. Begin Period Cash Flow is the amount of cash Tevogen Bio Holdings has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. View All Fundamentals
 
Begin Period Cash Flow  
First Reported
2010-12-31
Previous Quarter
148.6 K
Current Value
175.1 K
Quarterly Volatility
97.9 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tevogen Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tevogen Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 160.5 K, Interest Expense of 227.9 K or Selling General Administrative of 1.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Tevogen financial statements analysis is a perfect complement when working with Tevogen Bio Valuation or Volatility modules.
  
Check out the analysis of Tevogen Bio Correlation against competitors.

Latest Tevogen Bio's Begin Period Cash Flow Growth Pattern

Below is the plot of the Begin Period Cash Flow of Tevogen Bio Holdings over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Tevogen Bio's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tevogen Bio's overall financial position and show how it may be relating to other accounts over time.
Begin Period Cash Flow10 Years Trend
Slightly volatile
   Begin Period Cash Flow   
       Timeline  

Tevogen Begin Period Cash Flow Regression Statistics

Arithmetic Mean52,719
Geometric Mean10,106
Coefficient Of Variation185.77
Mean Deviation73,322
Median3,838
Standard Deviation97,936
Sample Variance9.6B
Range340.7K
R-Value0.64
Mean Square Error6.1B
R-Squared0.40
Significance0.01
Slope13,083
Total Sum of Squares143.9B

Tevogen Begin Period Cash Flow History

2025175.1 K
2024148.6 K
2023129.2 K
2022344.6 K

About Tevogen Bio Financial Statements

Tevogen Bio investors utilize fundamental indicators, such as Begin Period Cash Flow, to predict how Tevogen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Begin Period Cash Flow148.6 K175.1 K

Pair Trading with Tevogen Bio

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tevogen Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tevogen Bio will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tevogen Stock

  0.67PLX Protalix BiotherapeuticsPairCorr

Moving against Tevogen Stock

  0.32CRNX Crinetics PharmaceuticalsPairCorr
The ability to find closely correlated positions to Tevogen Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tevogen Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tevogen Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tevogen Bio Holdings to buy it.
The correlation of Tevogen Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tevogen Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tevogen Bio Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tevogen Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Tevogen Bio Holdings is a strong investment it is important to analyze Tevogen Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tevogen Bio's future performance. For an informed investment choice regarding Tevogen Stock, refer to the following important reports:
Check out the analysis of Tevogen Bio Correlation against competitors.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.36
Return On Assets
(5.42)
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.